2017/09/18
William Blair and BDA advise Olympus Partners on sale of Ritedose
a portfolio company of
has been acquired by
2017
William Blair acted as the lead financial advisor to the Ritedose Corporation, a portfolio company of Olympus Partners, in connection with its sale to Humanwell Healthcare and AGIC Capital. The transaction closed on September 13 and represents one of 14 William Blair transactions in the pharmaceutical services space completed in the past 12 months. William Blair advised Ritedose on the transaction in conjunction with its Asian affiliate, BDA Partners.
Transaction Highlights
- Deep sector expertise: Ritedose was attracted to William Blair and BDA’s extensive knowledge of the contract manufacturing and biopharmaceutical space, significant transaction experience with other outsourced pharmaceutical services companies, and strong relationships with potential buyers
- Process and execution excellence: William Blair and BDA designed and executed a highly competitive sale process with outreach to a global audience of highly interested strategic and financial buyers. This process drove a strong competitive dynamic, yielding an outstanding outcome and finding the right partner at a premium multiple for Ritedose
- Trusted guidance: William Blair and BDA’s transaction team was deeply involved in each step of the transaction process, including close collaboration with Ritedose in developing marketing materials, coordinating due diligence with multiple parties, and negotiating key contract terms
About Humanwell Healthcare
Humanwell Healthcare is a fully integrated China-based healthcare solutions provider. Since its establishment in 1993, Humanwell has endeavored to bring safe and effective medicines to the world through the quality of its products and integrity of its people.
About Ritedose
Ritedose is the leading manufacturer of unit-dose sterile pharmaceutical products in the United States using Blow-Fill-Seal technology. The company produces about 1.0 billion units annually for the respiratory and ophthalmic markets through its contract manufacturing business and operating subsidiary Ritedose Pharmaceuticals. The Ritedose Corporation was founded in 1995 and is based in Columbia, South Carolina.
About AGIC Capital
Founded in 2015, AGIC Capital is an Asian buyout investor focused on European and U.S. middle-market companies in high-growth industries. AGIC invests in companies with high-value-add technologies that significantly increase industrial productivity and efficiency, enable new applications and manufacturing methods, and drive innovation for industrial products and solutions.
About Olympus Partners
Founded in 1988, Olympus Partners is a private equity firm focused on providing equity capital for middle-market management buyouts and for companies needing capital for expansion. Olympus is an active, long-term investor across a broad range of industries, including restaurants, consumer products, healthcare services, financial services, and business services. Olympus manages in excess of $5.5 billion on behalf of corporate pension funds, endowment funds, and state-sponsored retirement programs.
About William Blair
William Blair’s investment banking group enables corporations, financial sponsors, and owner/entrepreneurs around the world to achieve their growth, liquidity, and financing objectives. Drawing on the collective intellectual capital and deep sector expertise of a global team that reaches across more than 15 cities on four continents, the investment banking group brings a rigorous and innovative approach to corporate board advisory projects, mergers and acquisitions, and equity and debt financing. From 2012 to 2016, the team advised on more than $230 billion in completed transaction volume.
1William Blair made a minority investment in and entered into a strategic alliance with BDA Partners in order to offer clients our collective global reach.
Recent transactions
divested majority stake in
to
2024
acquired majority stake in
2024
has been acquired by
2023
received investment from
2023
a subsidiary of
has acquired
2022
a portfolio company of
has been acquired by
2022
agreed to divest East Syracuse, New York facility to
2022
has sold minority stake to
2022
出售给Novo Holdings
2022
investment from
2021
has been acquired by
2021
a portfolio company of
has been acquired majority stake by
2021
拟出售给迈瑞医疗
2021
divested majority stake to
DCP Capital
2021
agreed to divest Couvet, Switzerland facility to WuXi AppTec
2021
raised Series B round from
2021
出售尼奥斯给松柏投资
2020
divested Escientia Life Sciences to Deccan Fine Chemicals
2020
divested significant stake in
Kehua Bio-Engineering to Gree Real Estate
2020
majority sale
2019